Developer docs
API playgroundTry for free, no card

Search company profiles

ORIC Pharmaceuticals

Full company profile

uuid0002831

Namestring
ORIC Pharmaceuticals
Legal namestring
Oric Pharmaceuticals, Inc.
Websiteurl
oricpharma.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California, with a research footprint in San Diego. The company is publicly traded on NASDAQ under the ticker ORIC following its April 2020 IPO. ORIC is organized around a proprietary resistance platform that targets three distinct mechanisms by which cancers evade therapy — innate resistance (unaddressed oncogenic drivers), acquired resistance (treatment-induced drivers), and bypass resistance (compensatory signaling) — with the goal of extending the clinical benefit of existing and emerging cancer treatments.

The pipeline consists of four differentiated small-molecule programs. The lead asset, rinzimetostat (ORIC-944), is an allosteric inhibitor of PRC2 via the EED subunit designed to address resistance in metastatic castration-resistant prostate cancer; Phase 1b data showed 55% PSA50 response rate and 59% ctDNA clearance, with the 400mg dose plus darolutamide selected for the 600-patient Himalayas-1 registrational Phase 3 trial initiating in H1 2026. Enozertinib (ORIC-114) is a brain-penetrant irreversible EGFR inhibitor targeting exon 20 insertion and PACC mutations in NSCLC, with reported 67–80% ORR in EGFR-mutant disease and intracranial activity; it is being evaluated both as monotherapy and in combination with J&J's amivantamab. Earlier-stage assets include ORIC-533 (CD73 inhibitor for multiple myeloma, in a Pfizer clinical collaboration) and ORIC-613 (PLK4 inhibitor in preclinical development for TRIM37-high tumors).

The business model is pre-commercial: ORIC generates no product revenue today, and access to its investigational compounds is restricted to patients enrolled in clinical trials across ten-plus countries. Future revenue, contingent on regulatory approval, is expected to come from direct pharmaceutical sales supplemented by out-licensing or co-promotion arrangements (consistent with the Pfizer and Janssen clinical collaborations already in place). The company has raised more than $900 million in private and public capital since 2018, holds $413 million in cash extending runway into H2 2028, and is led by a management team and board with a track record of developing and exiting oncology assets at Ignyta (Roche), Aragon (J&J), Seragon (Roche), Medivation (Pfizer), and Pharmacyclics.

Short descriptiontext

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies that target cancer resistance mechanisms, with a lead Phase 3 program (rinzimetostat) in prostate cancer and a brain-penetrant EGFR inhibitor (enozertinib) in NSCLC, both addressing major unmet needs in oncology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, cancer resistance therapies, precision oncology medicines, PRC2 inhibitors, EGFR inhibitors
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Oncology Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

ORIC Pharmaceuticals is a pre-revenue clinical-stage biopharmaceutical company. The company is focused on developing innovative cancer therapies with the goal of achieving regulatory approval and commercializing products. Revenue will be generated through sales of approved pharmaceutical products once clinical trials are successfully completed and regulatory approvals are obtained.

oricpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule oncology therapies designed to overcome cancer resistance. Its pipeline targets three resistance categories — innate, acquired, and bypass — and includes an allosteric PRC2/EED inhibitor (rinzimetostat) for metastatic castration-resistant prostate cancer, a brain-penetrant EGFR inhibitor (enozertinib) for NSCLC with exon 20 and PACC mutations, a CD73 inhibitor (ORIC-533) for multiple myeloma, and a preclinical PLK4 inhibitor (ORIC-613). All candidates are investigational and currently accessed only through clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Rinzimetostat 55% PSA50 response rate in metastatic castration-resistant prostate cancer patients
+4 more records
Product overview1 text field

ORIC Pharmaceuticals is a clinical-stage oncology company focused on developing therapies that address cancer resistance mechanisms. The company's resistance platform targets three areas: innate resistance (unaddressed oncogenic drivers), acquired resistance (induced/enriched oncogenic drivers from treatment), and bypass resistance (compensatory signaling pathways). The clinical-stage portfolio includes: Rinzimetostat (ORIC-944), a PRC2 allosteric inhibitor via EED subunit for prostate cancer; Enozertinib (ORIC-114), a brain-penetrant EGFR inhibitor for NSCLC with EGFR exon 20 and PACC mutations; ORIC-533, a CD73 inhibitor for multiple myeloma; and ORIC-613, a PLK4 inhibitor in preclinical development for TRIM37-high cancers.

Product and service4 records
1Rinzimetostat (ORIC-944)
CategoryClinical-stage oncology drug candidate (allosteric PRC2/EED inhibitor)
Description

A potent and selective allosteric inhibitor of PRC2 via the EED subunit designed to have superior drug properties over EZH2 inhibitors, including longer clinical half-life, robust target engagement, and a favorable safety profile. Efficacious in ARPI-sensitive and -resistant prostate cancer models and being developed for patients with metastatic castration-resistant prostate cancer who have progressed after abiraterone, in combination with androgen receptor pathway inhibitors such as darolutamide and apalutamide. Demonstrated 55% PSA50 response rate, 59% ctDNA clearance, and 84% 5-month radiographic progression-free survival at the selected Phase 3 dose.

2Enozertinib (ORIC-114)
CategoryClinical-stage oncology drug candidate (brain-penetrant EGFR inhibitor)
Description

A brain-penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR with high potency against exon 20 insertion mutations and atypical PACC mutations. Demonstrates greater brain exposure compared with other compounds and strong anti-tumor activity in intracranial lung cancer models. Being developed for NSCLC patients with EGFR exon 20 insertions, PACC mutations, and other atypical EGFR mutations, including those with CNS metastases, as monotherapy and in combination with amivantamab and chemotherapy. Demonstrated 67–80% ORR in EGFR-mutant NSCLC and 35% ORR in HER2 exon 20 mutated NSCLC with mostly Grade 1–2 adverse events.

3ORIC-533
CategoryClinical-stage oncology drug candidate (CD73 inhibitor)
Description

A small molecule CD73 inhibitor with potential best-in-class properties being developed for multiple myeloma. Designed to reverse immunosuppression and act as an immunomodulatory therapy. Being advanced through clinical development in collaboration with Pfizer.

4ORIC-613
CategoryPreclinical-stage oncology drug candidate (PLK4 inhibitor)
Description

A potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor demonstrating synthetic lethality in TRIM37-high cancer models, including neuroblastoma and breast cancer. Currently in preclinical development.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Johnson & Johnson (Janssen)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Clinical trial collaboration with Johnson & Johnson's Janssen unit to evaluate enozertinib (ORIC-114) in combination with amivantamab and hyaluronidase-lpuj subcutaneous injection (SC amivantamab) in patients with first-line NSCLC with EGFR exon 20 insertion mutations.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-22
Description

Clinical development collaboration with Pfizer for a Phase 2 study of ORIC-533 in multiple myeloma. Pfizer made a $25 million equity investment in ORIC. The collaboration leveraged Pfizer's capabilities to advance ORIC-533 into combination therapy with Pfizer's elranatamab, extending ORIC's cash runway into H1 2025.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing medicines targeting the chromatin regulatory system. Highly comparable to ORIC given overlapping interest in PRC2/epigenetic biology, similar development stage, and comparable small molecule oncology strategy.

TypeDirect peer
Description

Clinical-stage precision oncology company developing novel targeted therapies including RAS(ON) inhibitors. Comparable in size, public-stage, clinical focus, and emphasis on differentiated mechanisms of action addressing cancer resistance and difficult targets.

TypeDirect peer
Description

Clinical-stage precision oncology company developing medicines against undrugged targets, including allosteric and mutant-selective approaches. Directly comparable in clinical-stage model, mechanism-driven discovery, and small-molecule strategy.

TypeDirect peer
Description

Clinical-stage precision oncology company developing menin inhibitors (ziftomenib) and tipifarnib for HRAS-mutant tumors. Comparable size, stage, and clinical-stage precision oncology model targeting defined genetic patient populations.

TypeDirect peer
Description

Clinical-stage precision oncology company developing MAPK pathway inhibitors. Highly comparable as a public clinical-stage biotech with multiple programs in oncology addressing defined resistance mechanisms in a similar development profile.

6Nuvalent
TypeDirect peer
Description

Clinical-stage precision oncology company developing kinase inhibitors including zidesamtinib for ROS1 and neladalkib for ALK in NSCLC. Directly comparable to ORIC's enozertinib in CNS-active EGFR targeting and clinical-stage model.

TypeBroad incumbent
Description

Global pharma owner of Xtandi (enzalutamide), the leading ARPI for mCRPC. Direct competitive incumbent in the indication where ORIC's rinzimetostat Phase 3 will compete, with established commercial infrastructure and payer access.

TypeBroad incumbent
Description

Global pharma that owns Nubeqa (darolutamide), the ARPI being combined with ORIC's rinzimetostat in the Phase 3 Himalayas-1 trial. As the combination partner, Bayer is both a strategic ally and an entrenched competitor in mCRPC.

TypeBroad incumbent
Description

Global oncology-focused pharma that acquired Epizyme, gaining tazemetostat (EZH2 inhibitor, an FDA-approved PRC2 inhibitor for epithelioid sarcoma and follicular lymphoma). Direct mechanism competitor to ORIC's rinzimetostat in PRC2 oncology.

TypeBroad incumbent
Description

Global pharma developing valemetostat (EZH1/2 dual inhibitor) for lymphoma. A direct epigenetic mechanism competitor in the PRC2 inhibitor space and a major oncology innovator with ADC and other targeted programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors32 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ORIC Pharmaceuticals

Clinical-stage Oncology Pharmaceuticalsoricpharma.com

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies that target cancer resistance mechanisms, with a lead Phase 3 program (rinzimetostat) in prostate cancer and a brain-penetrant EGFR inhibitor (enozertinib) in NSCLC, both addressing major unmet needs in oncology.

What ORIC Pharmaceuticals does

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California, with a research footprint in San Diego. The company is publicly traded on NASDAQ under the ticker ORIC following its April 2020 IPO. ORIC is organized around a proprietary resistance platform that targets three distinct mechanisms by which cancers evade therapy — innate resistance (unaddressed oncogenic drivers), acquired resistance (treatment-induced drivers), and bypass resistance (compensatory signaling) — with the goal of extending the clinical benefit of existing and emerging cancer treatments.

The pipeline consists of four differentiated small-molecule programs. The lead asset, rinzimetostat (ORIC-944), is an allosteric inhibitor of PRC2 via the EED subunit designed to address resistance in metastatic castration-resistant prostate cancer; Phase 1b data showed 55% PSA50 response rate and 59% ctDNA clearance, with the 400mg dose plus darolutamide selected for the 600-patient Himalayas-1 registrational Phase 3 trial initiating in H1 2026. Enozertinib (ORIC-114) is a brain-penetrant irreversible EGFR inhibitor targeting exon 20 insertion and PACC mutations in NSCLC, with reported 67–80% ORR in EGFR-mutant disease and intracranial activity; it is being evaluated both as monotherapy and in combination with J&J's amivantamab. Earlier-stage assets include ORIC-533 (CD73 inhibitor for multiple myeloma, in a Pfizer clinical collaboration) and ORIC-613 (PLK4 inhibitor in preclinical development for TRIM37-high tumors).

The business model is pre-commercial: ORIC generates no product revenue today, and access to its investigational compounds is restricted to patients enrolled in clinical trials across ten-plus countries. Future revenue, contingent on regulatory approval, is expected to come from direct pharmaceutical sales supplemented by out-licensing or co-promotion arrangements (consistent with the Pfizer and Janssen clinical collaborations already in place). The company has raised more than $900 million in private and public capital since 2018, holds $413 million in cash extending runway into H2 2028, and is led by a management team and board with a track record of developing and exiting oncology assets at Ignyta (Roche), Aragon (J&J), Seragon (Roche), Medivation (Pfizer), and Pharmacyclics.

ORIC Pharmaceuticals firmographics

Firmographics
Name
ORIC Pharmaceuticals
Legal name
Oric Pharmaceuticals, Inc.
Website
https://oricpharma.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies that target cancer resistance mechanisms, with a lead Phase 3 program (rinzimetostat) in prostate cancer and a brain-penetrant EGFR inhibitor (enozertinib) in NSCLC, both addressing major unmet needs in oncology.
Ownership category
akta.pro rank

ORIC Pharmaceuticals industry classification

Industry
Product category
Clinical-stage Oncology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oncology drug development
  • Cancer resistance therapies
  • Precision oncology medicines
  • PRC2 inhibitors
  • EGFR inhibitors

Where ORIC Pharmaceuticals is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

ORIC Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: ORIC Pharmaceuticals is a pre-revenue clinical-stage biopharmaceutical company. The company is focused on developing innovative cancer therapies with the goal of achieving regulatory approval and commercializing products. Revenue will be generated through sales of approved pharmaceutical products once clinical trials are successfully completed and regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

ORIC Pharmaceuticals product offering

Product offering

Core offering

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule oncology therapies designed to overcome cancer resistance. Its pipeline targets three resistance categories — innate, acquired, and bypass — and includes an allosteric PRC2/EED inhibitor (rinzimetostat) for metastatic castration-resistant prostate cancer, a brain-penetrant EGFR inhibitor (enozertinib) for NSCLC with exon 20 and PACC mutations, a CD73 inhibitor (ORIC-533) for multiple myeloma, and a preclinical PLK4 inhibitor (ORIC-613). All candidates are investigational and currently accessed only through clinical trials.

Product overview

ORIC Pharmaceuticals is a clinical-stage oncology company focused on developing therapies that address cancer resistance mechanisms. The company's resistance platform targets three areas: innate resistance (unaddressed oncogenic drivers), acquired resistance (induced/enriched oncogenic drivers from treatment), and bypass resistance (compensatory signaling pathways). The clinical-stage portfolio includes: Rinzimetostat (ORIC-944), a PRC2 allosteric inhibitor via EED subunit for prostate cancer; Enozertinib (ORIC-114), a brain-penetrant EGFR inhibitor for NSCLC with EGFR exon 20 and PACC mutations; ORIC-533, a CD73 inhibitor for multiple myeloma; and ORIC-613, a PLK4 inhibitor in preclinical development for TRIM37-high cancers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rinzimetostat (ORIC-944) A potent and selective allosteric inhibitor of PRC2 via the EED subunit designed to have superior drug properties over EZH2 inhibitors, including longer clinical half-life, robust target engagement, and a favorable safety profile. Efficacious in ARPI-sensitive and -resistant prostate cancer models and being developed for patients with metastatic castration-resistant prostate cancer who have progressed after abiraterone, in combination with androgen receptor pathway inhibitors such as darolutamide and apalutamide. Demonstrated 55% PSA50 response rate, 59% ctDNA clearance, and 84% 5-month radiographic progression-free survival at the selected Phase 3 dose.
  • Enozertinib (ORIC-114) A brain-penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR with high potency against exon 20 insertion mutations and atypical PACC mutations. Demonstrates greater brain exposure compared with other compounds and strong anti-tumor activity in intracranial lung cancer models. Being developed for NSCLC patients with EGFR exon 20 insertions, PACC mutations, and other atypical EGFR mutations, including those with CNS metastases, as monotherapy and in combination with amivantamab and chemotherapy. Demonstrated 67–80% ORR in EGFR-mutant NSCLC and 35% ORR in HER2 exon 20 mutated NSCLC with mostly Grade 1–2 adverse events.
  • ORIC-533 A small molecule CD73 inhibitor with potential best-in-class properties being developed for multiple myeloma. Designed to reverse immunosuppression and act as an immunomodulatory therapy. Being advanced through clinical development in collaboration with Pfizer.
  • ORIC-613 A potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor demonstrating synthetic lethality in TRIM37-high cancer models, including neuroblastoma and breast cancer. Currently in preclinical development.

Quantifiable outcome

  • Rinzimetostat 55% PSA50 response rate in metastatic castration-resistant prostate cancer patients
  • +4 more outcomes

Companies that use ORIC Pharmaceuticals

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

ORIC Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ORIC Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Johnson & Johnson (Janssen)coreStrategic or Co-development Partner · 24 February 2026Clinical trial collaboration with Johnson & Johnson's Janssen unit to evaluate enozertinib (ORIC-114) in combination with amivantamab and hyaluronidase-lpuj subcutaneous injection (SC amivantamab) in patients with first-line NSCLC with EGFR exon 20 insertion mutations.
  • PfizercoreStrategic or Co-development Partner · 22 December 2022Clinical development collaboration with Pfizer for a Phase 2 study of ORIC-533 in multiple myeloma. Pfizer made a $25 million equity investment in ORIC. The collaboration leveraged Pfizer's capabilities to advance ORIC-533 into combination therapy with Pfizer's elranatamab, extending ORIC's cash runway into H1 2025.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

ORIC Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Foghorn Therapeutics: Clinical-stage precision oncology company developing medicines targeting the chromatin regulatory system. Highly comparable to ORIC given overlapping interest in PRC2/epigenetic biology, similar development stage, and comparable small molecule oncology strategy.
  • Revolution Medicines: Clinical-stage precision oncology company developing novel targeted therapies including RAS(ON) inhibitors. Comparable in size, public-stage, clinical focus, and emphasis on differentiated mechanisms of action addressing cancer resistance and difficult targets.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing medicines against undrugged targets, including allosteric and mutant-selective approaches. Directly comparable in clinical-stage model, mechanism-driven discovery, and small-molecule strategy.
  • Kura Oncology: Clinical-stage precision oncology company developing menin inhibitors (ziftomenib) and tipifarnib for HRAS-mutant tumors. Comparable size, stage, and clinical-stage precision oncology model targeting defined genetic patient populations.
  • Erasca: Clinical-stage precision oncology company developing MAPK pathway inhibitors. Highly comparable as a public clinical-stage biotech with multiple programs in oncology addressing defined resistance mechanisms in a similar development profile.
  • Nuvalent: Clinical-stage precision oncology company developing kinase inhibitors including zidesamtinib for ROS1 and neladalkib for ALK in NSCLC. Directly comparable to ORIC's enozertinib in CNS-active EGFR targeting and clinical-stage model.

Broad incumbents

  • Astellas Pharma: Global pharma owner of Xtandi (enzalutamide), the leading ARPI for mCRPC. Direct competitive incumbent in the indication where ORIC's rinzimetostat Phase 3 will compete, with established commercial infrastructure and payer access.
  • Bayer: Global pharma that owns Nubeqa (darolutamide), the ARPI being combined with ORIC's rinzimetostat in the Phase 3 Himalayas-1 trial. As the combination partner, Bayer is both a strategic ally and an entrenched competitor in mCRPC.
  • Ipsen: Global oncology-focused pharma that acquired Epizyme, gaining tazemetostat (EZH2 inhibitor, an FDA-approved PRC2 inhibitor for epithelioid sarcoma and follicular lymphoma). Direct mechanism competitor to ORIC's rinzimetostat in PRC2 oncology.
  • Daiichi Sankyo: Global pharma developing valemetostat (EZH1/2 dual inhibitor) for lymphoma. A direct epigenetic mechanism competitor in the PRC2 inhibitor space and a major oncology innovator with ADC and other targeted programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

ORIC Pharmaceuticals social profiles

Digital presence

ORIC Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ORIC Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles17 records

ORIC Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors32 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ORIC Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ORIC Pharmaceuticals

What does ORIC Pharmaceuticals do?

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule oncology therapies designed to overcome cancer resistance. Its pipeline targets three resistance categories — innate, acquired, and bypass — and includes an allosteric PRC2/EED inhibitor (rinzimetostat) for metastatic castration-resistant prostate cancer, a brain-penetrant EGFR inhibitor (enozertinib) for NSCLC with exon 20 and PACC mutations, a CD73 inhibitor (ORIC-533) for multiple myeloma, and a preclinical PLK4 inhibitor (ORIC-613). All candidates are investigational and currently accessed only through clinical trials.

Is ORIC Pharmaceuticals a public or private company?

ORIC Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was ORIC Pharmaceuticals founded?

ORIC Pharmaceuticals was founded in 2014. It employs 101 to 250 people.

Where is ORIC Pharmaceuticals based?

ORIC Pharmaceuticals is headquartered in South San Francisco, United States, in the North America region.

How does ORIC Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are ORIC Pharmaceuticals's main competitors?

Direct peers on record are Foghorn Therapeutics, Revolution Medicines, Black Diamond Therapeutics, Kura Oncology, Erasca and Nuvalent. Broad incumbents are Astellas Pharma, Bayer, Ipsen and Daiichi Sankyo.

Does ORIC Pharmaceuticals have an API?

No public API is recorded for ORIC Pharmaceuticals.

What industry is ORIC Pharmaceuticals in?

ORIC Pharmaceuticals's product category is Clinical-stage Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldOric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at CitigroupCitigroup raised its price target on Oric Pharmaceuticals to $17 from $16, maintaining a Buy rating. The company reported a Q3 loss of $0.44 per share, missing the $0.39 consensus estimate. Analysts have a consensus target of $21.33.TradingViewOric Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $21.64, Implies 188% UpsideAnalysts' average price target for Oric Pharmaceuticals fell to $21.64 from $22.75, implying about 188% upside from the Nov. 16 close. The consensus remains a Buy across 16 analysts, with 15 Buys, 1 Hold, and 0 Sells.TradingViewOric Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $21.79, Implies 190% UpsideAnalysts' average price target for Oric Pharmaceuticals fell to $21.79 from $22.75, implying about 190% upside from the Nov. 16 close. The consensus remains a Buy across 16 analysts, with 15 Buys, 1 Hold, and 0 Sells.TradingViewCitigroup maintains ORIC Pharmaceuticals at Buy, raises price target to $17 from $16Citigroup maintained ORIC Pharmaceuticals at Buy and raised its price target to $17 from $16, a 6.2% increase. The target implies 126.1% upside from the Nov 16 close of $7.52. Recent analyst price targets range from $14 to $26.Stock TitanORIC starts Phase 3 rinzimetostat prostate trialORIC Pharmaceuticals reported Q3 2026 results and program updates, initiating the Himalayas-1 Phase 3 trial for rinzimetostat in mCRPC and presenting enozertinib data at ESMO 2026. The company holds $345.4 million in cash and investments, expected to fund operations into H2 2028.TradingViewOric Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $22.75, Implies 153% UpsideAnalysts' average price target for Oric Pharmaceuticals rose to $22.75 from $21.71, implying about 153% upside from the Nov. 11 close. The consensus remains Buy across 14 analysts, with 13 Buys, 1 Hold, and 0 Sells.TradingViewORIC: Two phase III paths advance, supported by PRC2 evidence and enozertinib’s CNS activityRinzimetostat's phase III prostate study is underway with topline expected in H1 2028, while enozertinib showed systemic and CNS activity in atypical EGFR NSCLC. Pfizer's delayed MEVPRO-1 may be supportive, and enozertinib's phase III is planned for H1 2027.Investing.comORIC at stifel 2026 healthcare conference: pipeline bets and trial delaysORIC Pharmaceuticals presented at the Stifel 2026 Healthcare Conference, stating its oncology pipeline remains on track despite Pfizer's delayed MEVPRO-1 trial. The company highlighted its Phase III rinzimetostat trial (Himalayas-1) and enozertinib Phase II data, with a Phase III planned for 2025. It expects top-line data in H1 2028.Investing.comORIC Pharmaceuticals at guggenheim healthcare conference: late-stage pushORIC Pharmaceuticals outlined its late-stage oncology strategy at the Guggenheim Healthcare Innovation Conference, focusing on rinzimetostat in prostate cancer and enozertinib in lung cancer. The company reported $388 million in cash and investments with a runway into 2028, and enozertinib showed an 80% overall response rate in atypical EGFR mutations. Management expects top-line data for rinzimetostat in the first half of 2028.American Banking and Market NewsOric Pharmaceuticals, Inc. $ORIC Stock Sold by Candriam S.C.A.Candriam S.C.A. reduced its stake in Oric Pharmaceuticals by 33.2% in Q3, selling 391,643 shares and holding 788,125 shares worth $10.655 million. Analysts have a consensus "Moderate Buy" rating with an average target price of $21.25, while insiders sold 105,000 shares in the last quarter.